Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $45.00 Price Target at Needham & Company LLC

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price objective lifted by Needham & Company LLC from $32.00 to $45.00 in a report issued on Thursday, Benzinga reports. The firm currently has a buy rating on the stock. RYTM has been the subject of a number of other research reports. Wells Fargo & Company increased […]

Leave a Reply

Your email address will not be published.

Previous post PayPal’s (PYPL) “In-Line” Rating Reiterated at Evercore ISI
Next post EchoStar (NASDAQ:SATS) Receives New Coverage from Analysts at StockNews.com